These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23177300)

  • 1. Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors.
    Rogers JH; Goldstein I; Kandzari DE; Köhler TS; Stinis CT; Wagner PJ; Popma JJ; Jaff MR; Rocha-Singh KJ
    J Am Coll Cardiol; 2012 Dec; 60(25):2618-27. PubMed ID: 23177300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endovascular Therapy for Arteriogenic Erectile Dysfunction With a Novel Sirolimus-Eluting Stent.
    Schönhofen J; Räber L; Knöchel J; Keo HH; Regli C; Kostal F; Schumacher MC; Sammarchi L; Bechir M; Diehm N
    J Sex Med; 2021 Feb; 18(2):315-326. PubMed ID: 33454205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial.
    Kandzari DE; Leon MB; Popma JJ; Fitzgerald PJ; O'Shaughnessy C; Ball MW; Turco M; Applegate RJ; Gurbel PA; Midei MG; Badre SS; Mauri L; Thompson KP; LeNarz LA; Kuntz RE;
    J Am Coll Cardiol; 2006 Dec; 48(12):2440-7. PubMed ID: 17174180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, prospective, two-center comparison of sirolimus-eluting stent and zotarolimus-eluting stent in acute ST-elevation myocardial infarction: the SEZE trial.
    Chung WY; Kang J; Cho YS; Park HJ; Yang HM; Seo JB; Suh JW; Kim KI; Youn TJ; Kim SH; Chae IH; Zo JH; Kim MA; Choi DJ
    Chin Med J (Engl); 2012 Oct; 125(19):3373-81. PubMed ID: 23044291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
    Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
    J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unprotected left main coronary artery stenting with zotarolimus (Endeavor) drug-eluting stents: a single center retrospective experience.
    Simard T; Hibbert B; Chong AY; Ruchin P; Le May M; Labinaz M; Froeschl M; So D; Glover C; Marquis JF; O'Brien E
    Catheter Cardiovasc Interv; 2012 Aug; 80(2):E15-22. PubMed ID: 21805580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
    J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.
    Vermeersch P; Agostoni P; Verheye S; Van den Heuvel P; Convens C; Bruining N; Van den Branden F; Van Langenhove G
    J Am Coll Cardiol; 2006 Dec; 48(12):2423-31. PubMed ID: 17174178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): results from the ESSENCE-DIABETES trial.
    Kim WJ; Lee SW; Park SW; Kim YH; Yun SC; Lee JY; Park DW; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Lee BK; Lee NH; Cho YH; Shin WY; Lee SJ; Lee SW; Hyon MS; Bang DW; Park WJ; Kim HS; Chae JK; Lee K; Park HK; Park CB; Lee SG; Kim MK; Park KH; Choi YJ; Cheong SS; Yang TH; Jang JS; Her SH; Park SJ;
    Circulation; 2011 Aug; 124(8):886-92. PubMed ID: 21810659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents.
    Serruys PW; Silber S; Garg S; van Geuns RJ; Richardt G; Buszman PE; Kelbaek H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Ronden J; Bressers M; Gobbens P; Negoita M; van Leeuwen F; Windecker S
    N Engl J Med; 2010 Jul; 363(2):136-46. PubMed ID: 20554978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lesion Pattern in Patients With Erectile Dysfunction of Suspected Arterial Origin: An Angiographic Study.
    von Allmen RS; Nguyen DP; Birkhäuser FD; Bednar R; Kammer R; Do DD; Diehm N
    J Endovasc Ther; 2016 Feb; 23(1):76-82. PubMed ID: 26511893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Min KS; Park K; Park JK
    Eur Urol; 2011 Aug; 60(2):380-7. PubMed ID: 21458153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endovascular treatment for erectile dysfunction: an old paradigm revisited.
    Shishehbor MH; Philip F
    J Am Coll Cardiol; 2012 Dec; 60(25):2628-30. PubMed ID: 23177299
    [No Abstract]   [Full Text] [Related]  

  • 17. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease.
    Nikolsky E; Lansky AJ; Sudhir K; Doostzadeh J; Cutlip DE; Piana R; Su X; White R; Simonton CA; Stone GW
    Am Heart J; 2009 Oct; 158(4):520-526.e2. PubMed ID: 19781409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial.
    Leon MB; Mauri L; Popma JJ; Cutlip DE; Nikolsky E; O'Shaughnessy C; Overlie PA; McLaurin BT; Solomon SL; Douglas JS; Ball MW; Caputo RP; Jain A; Tolleson TR; Reen BM; Kirtane AJ; Fitzgerald PJ; Thompson K; Kandzari DE;
    J Am Coll Cardiol; 2010 Feb; 55(6):543-54. PubMed ID: 20152559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is There a Point to Performing a Penile Duplex Ultrasound?
    Morgado A; Diniz P; Silva CM
    J Sex Med; 2019 Oct; 16(10):1574-1580. PubMed ID: 31405766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.